Apertus Pharmaceuticals

Executive Summary

Apertus Pharmaceuticals is a US-based contract development and manufacturing organization (CDMO) specializing in small molecule active pharmaceutical ingredients (APIs), formulation development, and contract manufacturing. Founded in 2016 and headquartered in San Diego, the company serves clients from development through small to medium batch production, offering services such as sterile injectables, potent formulations, nasal sprays, topical products, and oral solid dosage forms. With a team experienced in fine chemicals, biotech, and pharmaceutics, Apertus positions itself as a flexible partner for emerging biopharma companies seeking specialized manufacturing capabilities. The CDMO market continues to grow, driven by outsourcing trends and demand for complex formulations. Apertus's focus on potent compounds and sterile manufacturing aligns with high-value segments, though the company faces competition from larger, established CDMOs. Its private status limits visibility into financials, but its differentiated capabilities may support steady growth through client wins and capacity expansions.

Upcoming Catalysts (preview)

• Q3 2026Facility Expansion or Capacity Addition60% success
• Q3 2026New Client Partnership or Long-Term Supply Agreement50% success
• Q4 2026Launch of New Service Offering (e.g., high-potency API manufacturing)40% success